Preliminary Results

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces its audited results for...

Interim results for the six months ended 30 September 2021

Click here to read our unaudited interim results for the six months ended 30 September 2021

FDA submission for Emergency Use Authorisation

Omega announces that following completion of the of US performance studies, its technology partner, Mologic Ltd has filed its submission to the U.S. Food...

Update on UK Government manufacturing contract

The Company remains in regular dialogue with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow antigen...

Launch of VISITECT® COVID-19 Antigen & Update

Omega launches our VISITECT® COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections. Read the...

CE-Mark of Mologic COVID-19 lateral flow antigen test

Omega announces that it has CE-Marked Mologic Ltd’s lateral flow antigen test for COVID-19, to be sold for professional-use under Omega’s VISITECT® brand...

UK Public Sector Contract disclosure

Omega's contract with DHSC to provide manufacturing capacity for COVID-19 lateral flow antigen tests estimated at £374 million. Read the full RNS here...

Contract with Screen4 for COVID-19 antibody laboratory-based testing service

Omega announces that it has signed a contract with Screen4 Ltd to provide a testing service using the Mologic ELISA antibody test for COVID-19 from our...

Directorate Change

We are pleased to announce the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate...

UK Government manufacturing contract

Omega announces that it has agreed a contract with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow...